Cargando…
Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bact...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670379/ https://www.ncbi.nlm.nih.gov/pubmed/34917048 http://dx.doi.org/10.3389/fmicb.2021.760698 |
_version_ | 1784614969226035200 |
---|---|
author | Hartley, M. Gill Norville, Isobel H. Richards, Mark I. Barnes, Kay B. Bewley, Kevin R. Vipond, Julia Rayner, Emma Vente, Andreas Armstrong, Stuart J. Harding, Sarah V. |
author_facet | Hartley, M. Gill Norville, Isobel H. Richards, Mark I. Barnes, Kay B. Bewley, Kevin R. Vipond, Julia Rayner, Emma Vente, Andreas Armstrong, Stuart J. Harding, Sarah V. |
author_sort | Hartley, M. Gill |
collection | PubMed |
description | Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated in vivo using the A/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with C. burnetii infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy in vivo. |
format | Online Article Text |
id | pubmed-8670379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86703792021-12-15 Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever Hartley, M. Gill Norville, Isobel H. Richards, Mark I. Barnes, Kay B. Bewley, Kevin R. Vipond, Julia Rayner, Emma Vente, Andreas Armstrong, Stuart J. Harding, Sarah V. Front Microbiol Microbiology Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated in vivo using the A/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with C. burnetii infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy in vivo. Frontiers Media S.A. 2021-11-30 /pmc/articles/PMC8670379/ /pubmed/34917048 http://dx.doi.org/10.3389/fmicb.2021.760698 Text en Crown copyright © 2021 Dstl. Authors: Gill, Norville, Richards, Barnes, Bewley, Vipond, Rayner, Vente, Armstrong and Harding. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Hartley, M. Gill Norville, Isobel H. Richards, Mark I. Barnes, Kay B. Bewley, Kevin R. Vipond, Julia Rayner, Emma Vente, Andreas Armstrong, Stuart J. Harding, Sarah V. Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever |
title | Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever |
title_full | Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever |
title_fullStr | Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever |
title_full_unstemmed | Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever |
title_short | Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever |
title_sort | finafloxacin, a novel fluoroquinolone, reduces the clinical signs of infection and pathology in a mouse model of q fever |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670379/ https://www.ncbi.nlm.nih.gov/pubmed/34917048 http://dx.doi.org/10.3389/fmicb.2021.760698 |
work_keys_str_mv | AT hartleymgill finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT norvilleisobelh finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT richardsmarki finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT barneskayb finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT bewleykevinr finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT vipondjulia finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT rayneremma finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT venteandreas finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT armstrongstuartj finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT hardingsarahv finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever |